MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...
DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback